- Home
- AMGN vs PDD Comparison
AMGN vs PDD Comparison
Compare AMGN & PDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- PDD
- Stock Information
- Founded
- AMGN 1980
- PDD 2015
- Country
- AMGN United States
- PDD Ireland
- Employees
- AMGN N/A
- PDD N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- PDD Business Services
- Sector
- AMGN Health Care
- PDD Consumer Discretionary
- Exchange
- AMGN Nasdaq
- PDD Nasdaq
- Market Cap
- AMGN 157.5B
- PDD 162.9B
- IPO Year
- AMGN N/A
- PDD 2018
- Fundamental
- Price
- AMGN $287.75
- PDD $113.80
- Analyst Decision
- AMGN Hold
- PDD Buy
- Analyst Count
- AMGN 20
- PDD 12
- Target Price
- AMGN $321.65
- PDD $137.83
- AVG Volume (30 Days)
- AMGN 2.0M
- PDD 6.6M
- Earning Date
- AMGN 08-05-2025
- PDD 08-25-2025
- Dividend Yield
- AMGN 3.34%
- PDD N/A
- EPS Growth
- AMGN 110.88
- PDD 22.63
- EPS
- AMGN 12.23
- PDD 9.23
- Revenue
- AMGN $34,917,000,000.00
- PDD $55,494,551,527.00
- Revenue This Year
- AMGN $7.96
- PDD $9.88
- Revenue Next Year
- AMGN $1.70
- PDD $15.46
- P/E Ratio
- AMGN $23.28
- PDD $12.37
- Revenue Growth
- AMGN 12.88
- PDD 35.67
- 52 Week Low
- AMGN $253.30
- PDD $87.11
- 52 Week High
- AMGN $339.17
- PDD $155.67
- Technical
- Relative Strength Index (RSI)
- AMGN 39.44
- PDD 58.38
- Support Level
- AMGN $281.65
- PDD $108.87
- Resistance Level
- AMGN $302.33
- PDD $115.85
- Average True Range (ATR)
- AMGN 6.81
- PDD 2.79
- MACD
- AMGN -2.59
- PDD -0.25
- Stochastic Oscillator
- AMGN 9.48
- PDD 42.47
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About PDD PDD Holdings Inc.
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. PDD aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from the increased productivity and new opportunities. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.